Lipids in the Intensive Care Unit:
Recommendations from the ESPEN Expert Group*

Philip C. Calder\textsuperscript{1,2}, Michael Adolph\textsuperscript{3}, Nicolaas E. Deutz\textsuperscript{4}, Teodoro Grau\textsuperscript{5}, Jacqueline K. Innes\textsuperscript{1}, Stanislaw Klek\textsuperscript{6}, Shaul Lev\textsuperscript{7}, Konstantin Mayer\textsuperscript{8}, Adina T. Michael-Titus\textsuperscript{9}, Lorenzo Pradelli\textsuperscript{10}, Mark Puder\textsuperscript{11}, Hester Vlaardingerbroek\textsuperscript{12}, and Pierre Singer\textsuperscript{7}

\textsuperscript{1}Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
\textsuperscript{2}National Institute for Health Research Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton SO16 6YD, United Kingdom
\textsuperscript{3}Department of Anesthesiology and Intensive Care Medicine, Nutrition Support Team, University Clinic Tuebingen, 72074 Tuebingen, Germany
\textsuperscript{4}Center for Translational Research in Aging & Longevity, Department of Health and Kinesiology, Texas A&M University, College Station, TX 77843, USA
\textsuperscript{5}Hospital Universitario Doce de Octubre, Madrid, Spain
\textsuperscript{6}General and Oncology Surgery Unit, Intestinal Failure Center, Stanley Dudrick’s Memorial Hospital, Skawina, Poland
\textsuperscript{7}Department of General Intensive Care and Institute for Nutrition Research, Rabin Medical Center, Hasharon Hospital and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
\textsuperscript{8}Department of Internal Medicine, Med. Clinik II, University Hospital Giessen and Marburg, 35392 Giessen, Germany
\textsuperscript{9}Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom
10 AdRes Health Economics and Outcomes Research, 10121 Turin, Italy

11 Vascular Biology Program and the Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts 02115, USA

12 Department of Pediatrics, Emma Children’s Hospital, Academic Medical Center, Amsterdam, The Netherlands

Author for correspondence: Philip C. Calder, Faculty of Medicine, University of Southampton, IDS Building, MP887 Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom

Email: pcc@soton.ac.uk

Phone: +44 2381205250

*Based upon the ESPEN Workshop “Lipids in the ICU” held in Tel Aviv, Israel on 23 and 24 November 2014

Running title: Lipids in the ICU

Key words: Lipid emulsion; Enteral nutrition; Parenteral nutrition; Sepsis; Critical illness; Surgery
Summary

This article summarizes the presentations given at an ESPEN Workshop on “Lipids in the ICU” held in Tel Aviv, Israel in November 2014 and subsequent discussions and updates. Lipids are an important component of enteral and parenteral nutrition support and provide essential fatty acids, a concentrated source of calories and building blocks for cell membranes. Whilst linoleic acid-rich vegetable oil-based enteral and parenteral nutrition is still widely used, newer lipid components such as medium-chain triglycerides and olive oil are safe and well tolerated. Fish oil (FO)-enriched enteral and parenteral nutrition appears to be well tolerated and confers additional clinical benefits, particularly in surgical patients, due to its anti-inflammatory and immune-modulating effects. Whilst the evidence base is not conclusive, there appears to be a potential for FO-enriched nutrition, particularly administered peri-operatively, to reduce the rate of complications and intensive care unit (ICU) and hospital stay in surgical ICU patients. The evidence for FO-enriched nutrition in non-surgical ICU patients is less clear regarding its clinical benefits and additional, well-designed large-scale clinical trials need to be conducted in this area. The ESPEN Expert Group supports the use of olive oil and FO in nutrition support in surgical and non-surgical ICU patients but considers that further research is required to provide a more robust evidence base.
1. Nutrition support of the critically ill patient

Patients in an intensive care unit (ICU) are heterogeneous and include surgical and medical patients, mechanically-ventilated or non-ventilated, obese or undernourished, preterm infants to older adults, requiring either short-term or long-term intensive care [1]. Nutrition support is critical in maintaining homeostasis in the ICU patient and to provide nutrients for the maintenance of lean body mass as well as repair and maintenance of organ function and support of defense and healing processes.

Enteral nutrition (EN) comprises specialized liquid nutrition delivered through a nasogastric or post-pyloric feeding tube into the stomach or small intestine (duodenum/jejunum), respectively [2]. The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend that EN should be given to all ICU patients who are not expected to be taking a full oral diet within three days [3].

Whilst ESPEN acknowledges that there are no definitive data supporting the early use of EN in terms of clinical outcomes, its guidelines recommend that hemodynamically stable critically ill patients who have a functioning gastrointestinal tract should be fed early (< 24 hours) using an appropriate amount of feed [3]. Early initiation of EN is also recommended by the American Society for Parenteral and Enteral Nutrition (ASPEN) and the Canadian Society of Critical Care Medicine (SCCM) [4], as well as the European Society of Intensive Care Medicine (ESICM) [5]. Administration of early EN in critically ill patients appears to also have a positive economic impact, with analysis suggesting that it is associated with significantly reduced costs relating to reduction in ICU stay and duration of mechanical ventilation compared with standard care [6].

There are a number of nutritional and non-nutritional benefits associated with early EN feeding. These include the maintenance of lean body mass, gut integrity, mucosal associated lymphoid tissue and muscle function, together with attenuation of oxidative stress [7]. Studies performed
The macronutrient content of several EN formulas used in clinical practice or in experimental studies is detailed in Table 1; it is evident that these differ greatly in content of macronutrients and in individual bioactive nutrients including glutamine, arginine and omega-3 fatty acids. Hence the metabolic, physiologic and clinical impact of different EN formulas will differ.

Parenteral nutrition (PN) is nutrition support provided through intravenous administration of nutrients such as amino acids, glucose, lipids (as emulsions), electrolytes, vitamins and trace elements. PN can be provided through a central venous line or through a peripheral intravenous line [12]. The ESPEN Guidelines for Parenteral Nutrition in Intensive Care recommend that all patients who are not expected to be on normal nutrition within 3 days should receive PN within 24 to 48 hours, if EN is contraindicated or if they cannot tolerate EN [13]. Furthermore, supplementary PN may also be initiated alongside EN in critically ill patients to help achieve energy and protein targets.

In terms of the safety of PN compared with EN in critically ill patients, whilst PN is associated with a lower mortality risk, particularly when compared to late EN, it has an increased risk of infectious complications [14,15]. Compared to standard care (oral diet when tolerated plus iv dextrose) in malnourished patients, EN appears to be associated with a lower risk of infection, whilst PN confers a lower risk of mortality as well as infection [16]. Supplemental PN may have clinical benefits in addition to reaching nutritional targets earlier, such as reduced risk of
nosocomial infections when initiated on days 4 - 8 alongside EN compared to EN alone [17]. However, a recent large scale multi-center randomized controlled study compared EN to PN and found no significant difference in mortality and infectious complications [18].

2. Lipids in enteral and parenteral nutrition

Lipids are used in enteral and parenteral nutrition primarily due to their high caloric content and are thus a good concentrated source of energy. As such, they lower the amount of carbohydrate that needs to be provided as part of the nutrition support. Lipids also provide the building blocks for cell membranes and provide essential fatty acids, thereby preventing essential fatty acid deficiency. The two essential essential fatty acids are the omega-6 (n-6) polyunsaturated fatty acid (PUFA) linoleic acid (LA) and the omega-3 (n-3) PUFA α-linolenic acid (ALA). In the body these may be converted to longer chain, more unsaturated derivatives that have important biological functions [19]. LA is the metabolic precursor of arachidonic acid (ARA) while ALA is the metabolic precursor of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The absence of lipids in artificial nutrition support regimens can result in the onset of essential fatty acid deficiency, especially in preterm infants, where there is insufficient synthesis of the omega-3 fatty acid DHA and the omega-6 fatty acid ARA from their essential precursors [20]. Lipids also allow for delivery of fat soluble vitamins.

Lipids used in nutrition support contain fats primarily in the form of triglycerides, with either medium-chain fatty acids (caprylic, capric, lauric and myristic acids), long-chain fatty acids (palmitic, oleic, linoleic and α-linolenic acids) or very long chain fatty acids (EPA and DHA) [19]. Table 2 details the nomenclature and sources of fatty acids commonly used as a component of nutrition support. Triglycerides rich in medium-chain fatty acids have been termed medium-chain triglycerides or MCTs. Soybean oil (SO) which is rich in linoleic acid, has been termed
long-chain triglycerides or LCTs, although strictly speaking any triglyceride composed of long-chain fatty acids is a LCT. Fatty acid chain length, and the presence, number and position of double bonds affect physical, physiological and functional properties of the fatty acid [19]. Hence, different fatty acids can influence, in different ways, a number of different physiological processes such as metabolism, inflammation, immune response, oxidative stress, blood coagulation, organ function and wound healing [19].

The blend of lipids used in nutrition support has evolved over time. This is well illustrated by considering the lipid emulsions (LEs) used in PN (Figure 1). The first generation of such LEs consisted purely of SO, with the second generation LEs including MCTs and structured lipids and the third generation beginning with the inclusion of olive oil (OO). Most recently third generation LEs containing fish oil (FO) have been introduced. Current commercially available LEs used in PN are detailed in Table 3 and include: pure SO; a 50:50 mixture of SO and MCTs (SO/MCT); inter-esterified SO and MCTs; a 20:80 mixture of soybean and olive oils (SO/OO; this is referred to herein as olive oil-based); a 40:50:10 mixture of SO, MCTs and FO (SO/MCT/FO); a 30:30:25:15 mixture of SO, MCTs, olive oil and FO (SO/MCT/OO/FO); and pure FO [21]. Additional components of lipid PN formulations include varying amounts of phytosterols (cholesterol-like structures that are present in plant oils); α-tocopherol and other fat-soluble bioactives, depending on the fat source; and phospholipids, usually phosphatidylcholine (sometimes called lecithin), as an emulsifier.

The major physiological effects of the key fatty acids found in different lipids are summarized elsewhere [19,22,23]. SO is a source of the essential omega-6 PUFA LA, which comprises about 50% of the fatty acids present and is the metabolic precursor of ARA. SO also contains some (~7% of fatty acids) of the essential omega-3 PUFA ALA. Because it is a precursor of ARA, an excess of LA is considered to promote inflammation, immunosuppression, coagulation, and fatty liver (hepatic steatosis) [24], although conclusive evidence for this is lacking. However,
it is clear that high amounts of LA do impair synthesis of the omega-3 PUFAs EPA and DHA [25].

MCTs, a source of medium-chain saturated fatty acids usually from coconut oil, are a good energy source whilst not affecting blood triglyceride levels. They are ketogenic and protein sparing, and are relatively resistant to peroxidation [26,27]. MCTs do not appear to impair liver, immune or lung function [26,27]. However, rapid infusion of such a lipid emulsion in patients suffering from acute respiratory distress syndrome resulted in a deterioration of lung function and hemodynamics [28].

OO, a source of oleic acid, is relatively neutral in its physiological effects, for example on immune function, inflammation and blood coagulation [29]. Because of its high content of monounsaturated fatty acids, OO is more resistant to peroxidation and oxidative stress than SO. Importantly, OO also preserves hepatobiliary function [30].

FO, a good source of EPA and DHA, is anti-inflammatory and may promote immune function and improve hepatic metabolism and liver function, including reversal of intestinal failure-induced fatty liver and cholestasis [19,23,31]. EPA and DHA also have anti-coagulation and anti-arrhythmic effects, and oppose the actions of omega-6 PUFAs [19,23]. However, being very long chain, highly unsaturated fatty acids, both EPA and DHA are prone to peroxidation.

Lipids provided in EN are subject to the normal intestinal processes of digestion and absorption, with the products appearing in the bloodstream as triglyceride components of chylomicrons. LEs in PN bypass intestinal processes and so may be metabolized differently from lipoproteins originating from the gut. Once infused, the LEs, comprising triglycerides stabilized with a shell of phospholipids, acquire endogenous apoproteins that enable binding to and activation of lipoprotein lipase [32]. The structure of LEs (i.e., their fatty acid composition) appears to affect their rate of plasma clearance and hence tissue uptake. Animal studies have demonstrated that synthetic triglycerides comprising two medium chain and one long chain fatty acid clear faster
than either MCTs or LCTs alone [33,34], an effect which is also observed in humans [35]. The addition of FO to an SO/MCT emulsion (SO:MCT:FO 40:50:10) resulted in faster plasma clearance than SO/MCT in both mice and humans [36,37].

The hydrolysis of circulating triglycerides arising from either enteral or parenteral lipid, yields free fatty acids that may enter adjacent tissues or remain in the circulation. The essential omega-3 PUFA ALA is not well incorporated into membrane phospholipids. However, the essential omega-6 PUFA LA, its metabolite ARA, and the metabolites of ALA EPA and DHA are incorporated into cell membrane phospholipids and into membrane lipid raft regions, thereby affecting the structure and function of membrane-bound proteins [19,21]. Thus these different PUFAs play a key role in cell membrane structure and function, regulation of gene expression and cell signaling pathways involved in apoptosis, metabolism, inflammation, cell-mediated immunity, blood clotting and organ function as well as synthesis of bioactive lipid mediators such as eicosanoids and docosanoids [19,21,22]. Eicosanoids are signaling molecules synthesized from 20-carbon PUFAs and include the prostaglandins (PGs), thromboxanes (TXs) and leukotrienes (LTs) produced from ARA and EPA. Lipoxins produced from ARA and resolvins produced from EPA are also eicosanoids. Docosanoids are signaling molecules synthesized from 22-carbon PUFAs and include the resolvins, protections and maresins produced from DHA.

Once incorporated into cell membranes, the metabolism of omega-6 and omega-3 PUFAs results in the production of eicosanoids and docosanoids that have differing roles in inflammation and immune response, platelet aggregation smooth-muscle contraction and so on [19]. The omega-6 PUFA ARA is metabolized to pro-inflammatory lipid mediators such as the 2-series PGs and TXs and the 4-series LTs [38,39]. It also gives rise to anti-inflammatory and inflammation resolving lipoxins [40]. Preclinical studies have highlighted the importance of lipid mediators produced from ARA in sepsis. Direct inhibition of cyclooxygenase-2 and 5-
lipoxygenase, enzymes involved in the synthesis of ARA-derived pro-inflammatory mediators (PGs, TXs, LTs), results in increased lipoxins which attenuate the inflammatory response and protect from sepsis [41]. Furthermore, administration of ARA-derived lipoxin A₄ in a mouse model of sepsis increased survival through reduction of systemic inflammation and blood bacterial load [42]. The omega-3 PUFAs EPA and DHA compete with ARA and result in synthesis of weaker pro-inflammatory 3-series PGs and TXs and 5-series LTs [43]. EPA and DHA also give rise to resolvins (both EPA and DHA), protectins and maresins (DHA only), which play a key role in resolution of inflammation, reduction of tissue injury and promotion of wound healing [44]. Resolvins reduce the inflammatory response via decreasing neutrophil invasion, reduction of synthesis of pro-inflammatory cytokines via inhibition of NF-κB, recruitment of monocytes, increased phagocytosis of apoptotic neutrophils and facilitation of removal of macrophages via the lymphatic system [44,45]. Rodent models have demonstrated that the inflammation-resolving effect of DHA-derived resolin D2 is associated with increased survival in bacterial sepsis [46]. Resolvin D2 was able to decrease local and systemic bacterial burden, excessive cytokine production and neutrophil recruitment, whilst increasing macrophage phagocytosis [46]. EPA and DHA also exert an anti-inflammatory effect acting through other mechanistic pathways, including suppression of nuclear factor kappa B signaling via activation of the cell surface GPR120 protein and the intracellular receptor peroxisome proliferator activated receptor γ, and thus inhibition of production of a range of pro-inflammatory cytokines, adhesion molecules, cyclooxygenase-2, inducible nitric oxide synthase and matrix metalloproteinases [19,43].

It is evident from the foregoing discussion that individual fatty acids have unique functional properties and that different members of the same fatty acid family (saturated, omega-6, omega-3) do not share the same properties [19]. For this reason, it is important that discussion of the role of the fatty acid composition of lipids to be used in nutritional support of patients in
the ICU (or elsewhere) should focus on individual fatty acids rather than on fatty acid families. Therefore, discussion of compositional properties such as the omega-6 to omega-3 ratio is not valuable. This is because this ratio can be altered in many different ways that may not have the same functional or clinical impact. For example, the omega-3 fatty acid component may be altered by using more ALA or by using more EPA+DHA and the outcome from those two scenarios is likely to be different. This is discussed further elsewhere [47,48].

3. Fish oil-enriched EN in critically ill patients

ESPEN guidelines state that an immune-modulating EN formula enriched with arginine, nucleotides and omega-3 fatty acids is superior to standard enteral formula in certain groups of patients, i.e. upper gastrointestinal surgical patients, trauma patients and patients with mild sepsis [3]. No benefit has been established in patients with severe sepsis, in whom an immune-modulating formula may be harmful and is therefore not recommended [3]. ASPEN and SCCM have previously issued similar guidelines [4], but these have been modified recently and suggest that immune-modulating enteral formulations (containing arginine with other agents, including omega-3 fatty acids, glutamine and nucleic acids) should not be used routinely in the medical ICU [49]. Consideration for these formulations should be reserved for patients with traumatic brain injury and perioperative patients in the surgical ICU [49].

Regarding critically ill patients with acute respiratory distress syndrome (ARDS) and severe acute lung injury (ALI), ESPEN guidelines state that such patients should receive an enteral formulation characterized by an anti-inflammatory lipid profile (i.e. omega-3 rich FO, borage oil) and antioxidants [3], a guideline previously supported by ASPEN and SCCM [4]. However, in 2013, the Canadian Clinical Practice Guidelines reviewed new study data investigating the effect of such EN formulas in critically ill patients with ALI/ARDS and downgraded the
recommendation to “should be considered” from “recommended” due to a diminished effect on mortality risk [50]. Furthermore, ASPEN in 2016 decided not to make any recommendation in this area [49]. Details of the studies discussed in the following sections may be found in Table 4.

3.1 ALI/ARDS

ARDS is characterized by diffuse pulmonary inflammation, increased vascular permeability and oedema [51,52]. Whilst a previous definition separated ALI from ARDS as a non-severe form (old definition [53]) and the term is still used in preclinical models, ALI is now defined as mild ARDS (Berlin Definition). Evidence from preclinical models of ALI/ARDS suggests that nutritional supplementation of EN with omega-3 fatty acids may improve vascular leakage, pulmonary inflammation and improve gas exchange and oxygenation [54,55].

Several clinical studies in patients with ALI/ARDS have shown that continuously-administered EN enriched with EPA, DHA, \( \gamma \)-linolenic acid (GLA, an omega-6 fatty acid present in borage oil) and anti-oxidants, resulted in improved oxygenation [56–59] and reduced duration of ventilation [56–58], decreased new organ failure [56,58,59] and shortened ICU stay [56,58–60] compared with standard EN. There is little evidence supporting the use of this formulation in mortality reduction in this patient population, apart from one study in patients with ARDS secondary to sepsis [58].

In contrast to these positive findings, two studies that utilized bolus administration of enteral FO in patients with ALI, found no clinical benefit compared with standard EN [61,62], with one trial being stopped early due to futility and reporting fewer ventilator- and ICU-free days, and a non-significant increase in the 60-day mortality in the FO group [61]. Compared to continuous administration, bolus delivery may not enable sufficient incorporation of EPA and DHA into cell membranes, which may have played a role in these negative findings. Furthermore, in one trial, whilst underfeeding occurred in both intervention and control groups, a five-fold higher
protein intake was reported in the control group, which is likely also to have contributed to the lack of effect seen in the study group [61,63].

A meta-analysis of 955 patients with ARDS/ALI concluded that FO-enriched EN had no effect on 28-day mortality [64]. However, a sensitivity analysis demonstrated that, on exclusion of the two studies delivering a bolus of FO, there is evidence that supports the use of continuous administration of EN containing FO in decreasing mortality in critically ill patients, including patients with ALI/ARDS [65]. However, ASPEN decided to make no recommendation at this time regarding the routine use of an enteral formulation characterized by an anti-inflammatory lipid profile (i.e. omega-3 rich FO, borage oil and antioxidants) in patients with ARDS and severe ALI, given the conflicting data [49].

### 3.2 Sepsis

Sepsis is associated with a hyper-inflammatory response which directly and indirectly causes widespread tissue damage, through the release of pro-inflammatory mediators, proteases and oxidants from activated macrophages, as well as vasodilators such as nitric oxide, which acts as a key mediator in septic shock [66,67].

Whilst no definitive study demonstrates that the use of EN enriched with omega-3 fatty acids results in improved outcomes for critically ill patients with sepsis, there does appear to be clinical benefit when administered in early-stage sepsis. Specifically, in patients without any sepsis-associated organ failure, administration of FO-enriched EN resulted in reduction in the progression of sepsis as well as in respiratory and cardiac failure and a reduced length of ICU stay compared with a lower lipid-containing EN [68].

### 3.3 Major abdominal surgery
There is evidence supporting the use of FO-enriched EN in major abdominal surgery. Perioperative administration of EN containing arginine, omega-3 fatty acids and RNA was reported to reduce post-operative complications and hospital length of stay in malnourished cancer patients undergoing major abdominal surgery versus standard post-operative EN [69]. Furthermore, immune-modulating EN (containing omega-3 fatty acids, arginine and glutamine) administered post-operatively to malnourished patients undergoing resection for pancreatic/gastric cancer resulted in a shorter hospital stay, fewer infectious complications and reduced morbidity and mortality compared to post-operative standard oligopeptide EN [70].

### 3.4 Severe trauma

There are few studies assessing the effect of FO-enriched EN specifically on trauma patients. One study administered pre-emptively FO-enriched EN (containing EPA, DHA, GLA and antioxidants) to severe trauma patients to assess its effect on the development of respiratory complications, but found no difference in the level of oxygenation (PaO2/FiO2 ratio), incidence of ARDS/ALI, duration of ventilation, length of ICU stay or 28-day mortality compared with a high fat/low carbohydrate EN formulation [71]. However, whilst red blood cell EPA, GLA and omega-3 index (the sum of EPA plus DHA) increased significantly in the study group, the optimal omega-3 index required for clinical efficacy failed to be reached, and this may have contributed to the study’s negative findings. This raises the importance of omega-3 fatty acid baseline measurement in ICU patients, to determine the extent of incorporation during supplementation; ultimately such measurements could be used as a predictor of therapeutic efficacy [72].

### 3.5 Benefit versus harm of immune-modulating EN in ICU patients

The ESPEN guidelines recommend the use of FO-enriched EN in subgroups of critically ill patients and there are a number of studies (discussed above) that show clinical benefit of such EN. However, a recent study has raised questions concerning the benefit and harm of immune-
modulating EN. Van Zanten et al. conducted a multi-centre trial in 301 mechanically ventilated critically ill patients, and found that high protein EN enriched with immune-modulating nutrients (glutamine, omega-3 PUFAs, selenium and anti-oxidants) had no effect on infections and other clinical endpoints (mortality, organ failure, duration of mechanical ventilation, length of stay) compared with standard high protein EN [73]. The study population comprised medical, surgical and trauma ICU patients. Sub-group analysis found that medical ICU patients had increased 6-month mortality rates in the enriched EN group suggesting that in this particular medical population, immune modulating EN should not be used. Specifically, these results, together with the increased mortality observed in the REDOXS trial [74] raise concerns over the safety of the glutamine component of the enteral feed in certain ICU patients.

4. Clinical and biochemical effects of different lipid emulsions in PN used in critically ill patients

ESPEN guidelines recommend that lipids should be an essential part of PN for energy and to ensure essential fatty acid provision, and that intravenous LEs can be administered safely at a rate of 0.7 g/kg up to 1.5 g/kg over 12 to 24 h [13]. However, the choice of lipid used in PN may have an effect on clinical outcomes in the critically ill patient.

4.1 Soybean oil-based lipid emulsions

As discussed in Section 2, pure SO may have a number of less desirable effects on physiological processes, such as promoting inflammation and suppressing immune function due to its high LA content, and a tendency for peroxidation due to its relatively low α-tocopherol content. Pure SO has also been associated with a number of complications including hyperbilirubinemia and intestinal failure associated liver disease (IFALD). SO intake may
increase the lung flow of lymph and pulmonary pressure, and decrease the partial pressure of oxygen in arterial blood (PaO$_2$) resulting in respiratory acidosis, and modify lipid metabolism when compared to second and third generation lipids [75,76].

There is evidence that SO-based PN might exacerbate the post-surgical inflammatory response in gastrointestinal surgery patients with severe surgical-related stress, and impair immune function when compared to standard glucose-containing PN [77]. The pro-inflammatory effect of the SO emulsion was not so pronounced in patients with moderate surgery-related stress. An immunosuppressive effect was also seen in polytrauma patients receiving early SO-containing PN, which was associated with higher rates of infection, reduced T cell function and lowered natural killer cell activity [78]. This was linked to longer duration of mechanical ventilation and longer ICU and hospital stay, compared to standard glucose-containing PN [78]. However, neither of these studies examined the impact of other lipids to which the effects of SO could be compared.

The accumulating evidence base has resulted in a recommendation from the German Society for Nutritional Medicine (DGEM) that pure SO LEs should no longer be used in PN support of critically ill patients [79]. DGEM will further refine its recommendation in its updated guidelines and will advise that ICU patients should receive second or third generation LEs with reduced content of omega-6 fatty acids (M. Adolph and K. Mayer, personal communication; [80]). ASPEN suggest withholding SO-based LEs during the first week following initiation of PN in the critically ill patient or limiting this to a maximum of 100 g/wk (often divided into 2 doses/wk) if there is concern about essential fatty acid deficiency [49].

### 4.2 Olive oil-based lipid emulsions

OO-based LEs appear to be a safe alternative to pure SO-based LEs, which is reflected in the ESPEN guidance that OO-based PN is well tolerated in critically ill patients [13]. Using OO-
based PN in adult surgical patients results in better fatty acid status, increased blood vitamin E concentration, decreased lipid peroxidation and decreased inflammatory variables [81–83]. However, the evidence base for the potential for OO-based LEs to improve clinical outcomes is not consistent. In surgical ICU patients administered OO-based PN for up to 28 days post-surgery, there was no difference in glycemic control, immune function, or inflammatory or oxidative stress markers compared to SO-based PN [84]. Mortality rate, incidence of nosocomial infections and acute renal failure, as well as length of stay, were all reported to be similar between the two groups. Mateu-de Antonio et al. also found no difference in the number or type of infections, length of ICU or hospital stay or mortality following an average duration of 19 days of post-operative OO-based PN compared to SO in surgical ICU patients [85].

4.3 SO/MCT-based lipid emulsions

There is good evidence that supports the use of SO/MCT LEs instead of pure SO in critically ill patients. A study in severely malnourished surgical patients receiving peri-operative total PN reported a significantly lower incidence of intra-abdominal abscesses with SO/MCT versus SO [86]. There was no reported difference in other infection rates or mortality. SO/MCT is also associated with a shorter period of mechanical ventilation in critically ill patients with COPD compared to SO [87].

4.4 Fish oil-containing lipid emulsions

ESPEN guidelines state that addition of EPA and DHA to LEs has demonstrable effects on cell membranes and inflammatory processes, and that FO-enriched lipid emulsions probably decrease length of stay in critically ill patients [13]. DGEM will also state that specific LEs enriched with omega-3 fatty acids may be considered for administration in critically ill patients (M. Adolph and K. Mayer, personal communication). There have been a number of studies
investigating the effect of FO-enriched PN in critically ill patients (see Tables 5, 6 and 7 for more details about the studies included in the following sections).

4.4.1 Fish oil-enriched PN in surgical ICU patients

Administration of FO-enriched PN in patients undergoing major surgical procedures appears to be effective in lowering the post-operative inflammatory response. For example, suppression of the pro-inflammatory cytokine IL-6 was reported following parenteral FO administration in elderly patients undergoing hip surgery compared to the absence of intravenous FO administration [88]. Furthermore, perioperative infusion of FO in cardiac surgery patients significantly increased platelet EPA and DHA and atrial tissue EPA together with a decrease in IL-6 concentrations, with no adverse effects reported compared with the saline control [89]. Compared to SO, perioperative FO-enriched PN in surgical ICU patients decreased post-operative serum IL-6 and whole blood tumor necrosis factor (TNF)-α production, and increased monocyte expression of human leukocyte antigen-DR (a marker of immune competence) [90]. This effect was associated with a shorter hospital stay in the FO-enriched PN group, but there was no difference in infection rate or mortality. Administration of FO-enriched PN (FO + SO) for 7 d post-gastrointestinal surgery resulted in significantly fewer incidences of systemic inflammatory response syndrome (SIRS) and significantly shorter hospital stay compared with SO alone [91]. There was also a trend towards fewer infectious complications in the FO-enriched PN group. Similar results were reported for short-term (3 d) pre-operative infusion of FO alone in gastrointestinal cancer patients awaiting surgery [92]. Administration of FO improved the post-operative immune response (decreased interleukin (IL)-6 and IL-10, decreased leukocyte oxidative burst, maintenance of monocyte percentage expressing human leukocyte antigen-DR and CD32, and increased neutrophil CD32 expression) but had no effect on post-operative infections or length of ICU or hospital stay [92].
There is also evidence supporting the post-operative administration of FO-containing PN in gastric surgery patients in improving post-surgical immune competence, lowering infection rate and shortening hospital stay. In elderly patients following colorectal cancer surgery, administration of PN containing FO + SO for 7 d resulted in lowered levels of IL-6 and TNF-α and fewer CD8 positive cells in the bloodstream, fewer infectious complications and incidences of SIRS, and shorter length of hospital stay compared with SO alone [93]. Furthermore, a study in gastric carcinoma patients undergoing major abdominal surgery reported that post-operative PN enriched with FO resulted in fewer infectious complications and a shorter hospital stay compared with standard PN [94]. A reduced infection rate was also found in gastrointestinal surgery patients following 5 days of post-operative PN containing OO/SO enriched with FO compared to OO/SO alone [95], whilst another study found a shorter length of hospital stay was associated with FO-enriched SO/MCT compared to SO alone in gastrointestinal surgery patients [96]. Decreased length of hospital stay was found to be associated with 5 days of post-operative administration of SO/MCT/OO/FO-containing PN compared to SO-based PN in gastrointestinal surgery patients [97]. Furthermore, in liver transplantation patients, FO-enriched PN given for 7 days post-surgery resulted in a decreased length of hospital stay compared to SO/MCT [98]. Perioperative administration of FO-enriched PN in surgical patients appears to have a beneficial effect on clinical outcomes as suggested by Heidt et al. from a study in coronary artery bypass graft patients which resulted in a shortened ICU stay compared to SO-based PN [99] and Tsekos et al.’s study in gastrointestinal surgery patients which resulted in decreased mortality, decreased requirement for mechanical ventilation and decreased hospital stay compared to SO/MCT-containing PN [100].

These findings are supported by a meta-analysis of 23 studies including 1,502 surgical and ICU patients which investigated the effects of FO-enriched PN compared with other LEs (SO, SO/MCT, OO/SO) on various clinical outcomes [101]. Whilst the authors found no effect on
mortality, FO-enriched PN resulted in a clinically and statistically significant reductions in
infection rate and in length of ICU and hospital stay. A smaller meta-analysis of 7 RCTs also
concluded that post-operative administration of FO-enriched PN in major abdominal surgery
patients has a beneficial effect on post-operative infection rates and length of ICU and hospital
stay [102]. Furthermore, a meta-analysis of five trials performed by Manzanares et al. found that
FO administered either parenterally or enterally resulted in a non-statistically significant trend
towards reduced duration of mechanical ventilation [103].

In addition to its positive effects on inflammation and immune function, FO-enriched PN may
help to preserve liver function in critically ill surgical patients. Decreased total bilirubin as well as
serum IL-6, TNF-α and nuclear factor kappa B was reported in gastrointestinal surgical patients
following post-operative administration of FO-enriched PN compared with SO/MCT [104]. Rates
of infectious complications and SIRS were comparable between the two groups. A similar study
also utilizing FO-enriched PN versus SO/MCT in post-operative patients, found similar results,
although statistical significance was not reached for the reductions in liver dysfunction, infection
rate and serum pro-inflammatory cytokines [105]. In comparison with pure SO, FO/SO (20:80)
administered post-operatively to major abdominal surgery patients resulted in significantly
decreased markers of liver dysfunction (ALT and AST), bilirubin and lipase [106]. Weight was
maintained in the FO-enriched PN group, as well as a tendency towards shorter ICU stay in
those patients at risk of sepsis [106]. Hence FO-enriched PN improved liver and pancreas
function in this patient population, and may have been a factor in reducing ICU stay for patients
at risk of sepsis. The newer composite SO/MCT/OO/FO (30:30:25:15) LE has also shown a
liver-protecting effect in post-operative patients requiring PN, resulting in significantly lower ALT,
AST and α-GST compared with OO/SO [107].

This liver-protective effect has also been demonstrated in liver transplantation patients, whereby
post-operative FO-enriched PN lowered ALT and prothrombin time as well as length of hospital
stay compared with PN containing SO/MCT [98]. Improvement in liver injury and a reduction in
the number of infectious morbidities was also reported for the FO-enriched PN group.

It is important to note that not all clinical studies in surgical ICU patients have been positive. Parenteral SO/MCT/OO/FO administered to gastric cancer surgical patients resulted in no
difference in efficacy, safety, tolerance or clinical outcomes (including post-operative
complications) compared with SO/MCT [108]. Metry et al. also found no difference in ventilation
requirement, duration of ICU or hospital stay or mortality following 7 days of post-operative
administration of parenteral SO/MCT/OO/FO compared to SO alone [109]. Furthermore, Wu et
al.’s study in gastrointestinal surgery patients found no difference in inflammatory markers (C-
reactive protein, IL-6, IL-10, TNF-α and transforming growth factor β1) or markers of oxidative
stress compared with SO/MCT [110].

A meta-analysis of 6 RCTs (306 surgical patients) did conclude that SO/MCT/OO/FO was
associated with lower hepatic enzymes, low-density lipoprotein, triglycerides and C-reactive
protein following post-operative administration compared with SO, but found no statistically
significant changes compared with SO/MCT [111]. There was no difference in adverse events or
length of hospital stay compared with either SO or SO/MCT.

Eicosanoids are involved in the control of platelet aggregation and so influence blood clotting
and bleeding time. TXA₂ and prostacyclin (PGI₂) are both produced from the omega-6 PUFA
ARA. TXA₂ is pro-aggregatory and PGI₂ is anti-aggregatory. EPA from FO decreases the ARA
content of the platelet membrane [112], so decreasing production of both TXA₂ and PGI₂ [112].
Instead, production of the EPA-derived eicosanoids TXA₃, which is a weak platelet aggregator,
and PGI₃ which is a potent inhibitor of platelet aggregation occurs [112]. Thus, FO results in
decreased platelet aggregation [112], which can increase bleeding and time to clotting. With
regard to this theoretical increased risk of bleeding with FO-based PN, studies to date have
shown that FO is safe to include in PN regimens and does not increase risk of bleeding. Acute pretreatment with omega-3 PUFAs in coronary artery bypass graft patients non-significantly affected the activity of platelets and did not influence postoperative blood loss [113].

Based on the evidence available and according to the new ESPEN guidelines on clinical nutrition in surgery, postoperative PN including omega-3-fatty acids should be started only in malnourished patients who cannot be adequately fed enterally and, therefore, require PN [114]. If PN is required post-operatively in the ICU, 2nd or 3rd generation lipid emulsions may be administered, and in the case of surgical complications, FO-containing PN is recommended.

4.4.2 Fish oil-enriched PN in non-surgical ICU patients

Compared to SO and SO/MCT, FO-enriched PN may provide clinical benefits for a wide range of ICU patients. In mechanically ventilated critically ill patients, FO-enriched PN resulted in a shorter duration of mechanical ventilation and a faster time to ICU discharge compared to lipid-free or SO-based PN [115]. In patients with acute pancreatitis, administration of FO-supplemented PN resulted in significantly decreased CRP in addition to better oxygenation index and fewer days of continuous renal replacement therapy compared with SO alone [116].

Clinical studies in patients with sepsis have shown that parenteral administration of either omega-6 or omega-3 fatty acids results in elevated concentrations of the respective free fatty acids several-fold, as well as appearance of the respective eicosanoids [117]. Hence PN containing FO should theoretically lead to increased levels of inflammation-resolving resolvins and associated clinical benefits. The latter is supported by some trials. Compared to standard care, FO administered to patients with sepsis resulted in a significant reduction in new organ dysfunction and lower maximum C-reactive protein concentrations [118]. A significant reduction in mortality was observed for patients with less severe sepsis. Furthermore, FO-enriched PN (SO/MCT/FO 50:40:10) administered to patients with sepsis or SIRS for 5 days
plasma EPA levels, decreased plasma IL-6, improved oxygenation (PO$_2$/FiO$_2$ ratio) and reduced length of hospital stay compared to SO/MCT [119]. However, several studies have failed to show any clinical benefit of FO-enriched PN in cases of sepsis or septic shock compared to either standard care, saline or SO-based PN [117,120–122], although one of these studies did find a non-statistically significant trend towards shorter ventilation time [117].

FO-enriched PN administered to critically ill medical and surgical patients may result in a significant reduction in the number of nosocomial infections compared to SO/MCT [123]. Time free of infection was also significantly longer in the FO-supplemented group, although there was no effect reported for ICU or hospital stay or 6-month mortality rate.

This lack of effect of FO-enriched PN on mortality rate compared to standard PN is confirmed by meta-analyses of 6 RCTs [124] and of 8 RCTs [125] in critically ill adults, the latter also finding no difference in infectious complications or ICU length of stay. There was weak evidence of a reduction of hospital length of stay associated with FO-enriched PN, but this was strongly influenced by one small study [125].

Not all trials investigating the use of FO-enriched PN in critically ill patients report positive outcomes. Administration of FO-enriched PN to medical ICU patients (with and without SIRS) had no effect on inflammatory markers (IL-6), incidence of infection, duration of mechanical ventilation, length of ICU stay or 28-day mortality compared with SO/MCT [126]. The study included severely ill patients that were at different stages of the inflammation/inflammation resolution cycle; hence the intervention may have been administered after termination of the initial inflammatory process in some patients. Timing of omega-3 fatty acid administration is important if hyper-inflammation is to be prevented, and from previously discussed studies, administration prior to commencement of inflammation is likely optimal. Furthermore, dosage levels of the administered FO also play a critical role in whether the intervention provides clinical
benefit. A study investigating the dose-dependent effects of FO-enriched PN in a range of ICU patients found that the most favorable effects on survival, infection rates and length of hospital stay occurred when parenteral FO was administered between 0.1 and 0.2 g/kg/d. A 26% lower antibiotic demand was associated with parenteral administration of FO between 0.15 and 0.20 g/kg/d [127].

5. Lipids and PN in pediatric patients

The joint European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and ESPEN guidelines on PN in pediatrics recommend that in small preterm infants, when EN is not possible, PN including lipids should be initiated as soon as possible after birth [128]. Intolerance to full EN is common in preterm infants, and results in a high incidence of postnatal growth failure.

Surveys of current practice in neonatal ICUs in Europe and the US show that there is a wide range in the timing and initial dose of lipid administration [129]. In the UK and Ireland, whilst a greater proportion of preterm infants start PN within 48 h, around one quarter of preterm infants still are not given PN until or after day 3 [130]. When considering a role for PN and lipids in preterm infants, the potential to improve neurodevelopmental outcomes should not be overlooked: DHA is critical in neurodevelopment with the brain comprising 60% of lipid, and with > 80% of brain DHA accumulating between 26-40 weeks gestation [131].

In preterm infants, there is concern regarding early lipid-containing PN and the risk of complications such as sepsis, bronchopulmonary dysplasia (BPD), hyperbilirubinemia, liver disease, persistent pulmonary hypertension of the newborn (PPHN) and thrombocytopenia. However, a meta-analysis of 14 studies investigating the effect of early (≤ 2 d) parenteral lipid in very low birth weight (VLBW) infants, found no difference in sepsis, BPD, growth or mortality rates compared to later (≥ 2 d) administration [132]. This is supported by a later RCT comparing
lipid-containing PN administered from birth to VLBW infants with standard PN from birth with lipids administered 2 d later, which reported no difference in growth, biochemical or clinical outcomes between the groups [133,134].

There is also a risk of hypertriglyceridemia associated with lipid administration in preterm infants, due to limited fat and muscle mass and thus decreased hydrolytic capacity from lipoprotein lipase. Whilst there is no specific indicator of lipid tolerance, as plasma triglyceride levels indicate plasma clearance, monitoring of plasma triglycerides is recommended. ESPGHAN recommends a safe triglyceride level of 2.85 mmol/l (250 mg/dl) in preterm infants and newborns [128], whilst ASPEN recommends 2.26 mmol/l (200 mg/dl) [135]. However, in one trial, hypertriglyceridemia of >3 mmol/l (>265 mg/dl) was not associated with neonatal morbidities [133].

IFALD is associated with chronic (>14 d) total PN (TPN), and incidence is directly related to TPN duration. Short bowel syndrome (SBS) accounts for 1.4% of all deaths for children under 4 y and is primarily related to the development of IFALD which is identified through biochemical parameters such as direct bilirubin levels >2 mg/dl (34 µmol/l), increased GGT, ALT, and serum bile acids [136,137]. Some 40-60% of patients with short bowel syndrome on TPN develop cholestasis, and a study published in 2005 reported that the mortality rate is approximately 78% if bilirubin remains > 3 mg/dl for 3 months, and increases to 90% if cholestasis is diagnosed and there is no weaning off TPN within a year of diagnosis, or failure to receive a liver transplant [138]. A Pediatric Intestinal Failure Consortium (PIFCon) retrospective analysis of clinical outcome data for infants with intestinal failure reported that of a cohort of 272 infants (< 1 y old and on prolonged TPN for > 2 months), the mortality rate was 27% and intestinal transplantation rate was 26% [139].
Besides prematurity and prolonged TPN use, other risk factors for IFALD include lack of enteral nutrition, multiple operative procedures, sepsis or inflammation, and possibly also nutrient deficiencies or toxicities associated with other components in lipid PN [140,141]. Preventative/treatment measures for IFALD may include cycling PN, feed advancement, prevention and aggressive treatment of sepsis, lipid reduction to ≤ 1 g/kg/d, altering the lipid being used in PN (see below), elimination of hepatotoxic medications, reduction of bacterial overgrowth, use of the bile acid ursodiol, reduction of transfusions and minimizing surgical procedures if possible [137,142–151], although the evidence in favour of some of these is weak [152]. Whilst IFALD/cholestasis may be reversed with elimination/reduction of lipids, cholestasis may be progressive whilst on PN. It may lead to liver cirrhosis, liver failure, liver transplant or death [153].

Regarding the choice of LE in PN for pediatric patients, it is suggested that high levels of omega-6 PUFAs and phytosterols found in SO can be hepatotoxic and lead to IFALD [154]. Phytosterols have been shown to antagonize the farnesoid-X-receptor (FXR) [155] which normally acts to suppress hepatic lipogenesis and bile acid synthesis. Thus, in the presence of phytosterols, those processes continue uncontrolled leading to both fatty liver and cholestasis. FO-containing PN may have a protective effect against IFALD due to the lower phytosterol content, higher omega-3 PUFA content, and higher α-tocopherol content, and to direct regulation of bile flow through eicosanoid-mediated mechanisms [156]. In pediatric patients with IFALD whose cholestasis was resolved with use of FO, decreased direct bilirubin levels and markers of liver injury were reported together with improvement in hepatic function [156,157]. However, some of these studies compared a group of infants receiving FO-based PN with an historic control group. Furthermore, some studies used pure FO LE rather than a lipid mix. Finally, many studies have lowered the lipid dose being used (generally to 1 g/kg/d) at the same
time as introducing FO-containing PN. Thus, it is difficult to disentangle the effects of the lower lipid dose from those of an alternative lipid mixture.

With regard to other potential clinical benefits of FO-enriched PN in preterm infants, an RCT in VLBW infants administered SO/MCT/OO/FO reported a significant increase in weight gain and increased plasma EPA and DHA (but no difference in ARA) compared to SO-based PN [134,158]. However, there were no differences in morbidity, mortality or biochemical outcomes between the two groups. Several studies concur regarding these outcomes with multi-component lipid PN versus other LEs [158–164].

FO-enriched PN given to infants undergoing major cardiac surgery may help ameliorate the post-operative inflammatory response. A study investigating the effects of parenteral SO/MCT/FO (40:50:10) given pre- and post-operatively to infants undergoing open heart surgery reported a lower inflammatory response post-surgery compared with SO alone [165]. Specifically the FO containing LE resulted in higher plasma phospholipid EPA and decreased plasma LTB₄ and lymphocytes. An earlier trial also found significantly lower TNF-α concentrations and a positive association with length of hospital stay in the SO/MCT/FO group compared with SO when given perioperatively in infants undergoing cardiac surgery [166].

In summary, for preterm infants, lipids given directly following birth at 2 g/kg/d appear safe according to short term studies. Emulsions with a mix of lipid sources including FO may offer benefits over SO alone, although long-lasting positive effects need to be proven.

6. Economic considerations for fish oil-enriched lipids in the ICU

Pradelli et al. performed an analysis of the cost-effectiveness of SO/MCT/OO/FO in surgical and ICU patients in four European countries (Italy, Germany, France and the UK) [167]. The
analysis considered costs associated with nutritional treatment, ICU stay, general ward stay and nosocomial infections as well as the benefits of FO-containing PN on infection rates and length of stay. The study concluded that the treatment costs associated with FO-enriched PN were completely offset by the savings made from the subsequent reduction in hospital stay and reduced antibiotic costs. Hence, FO-containing PN is cost-effective and beneficial for both ICU and non-ICU patients in hospitals in Italy, Germany, France and the UK compared with standard PN.

7. Future directions

7.1 Effects of omega-3 fatty acids in preclinical models of acute neurological injury

Spinal cord injury (SCI) is associated with significant social and healthcare burden [168]. In the acute phase following SCI, the initial lesion expands and results in a secondary injury wave, reflected in the progressive loss of grey matter within the spinal cord [169,170]. Secondary injury pathophysiology is characterized by activation of inflammatory pathways, increased glutamate release and vascular damage leading to ischaemia [171]. Preclinical studies involving rodent compression and hemisection SCI models, at thoracic and cervical levels, have demonstrated that acute DHA injection in the range of 250–500 nmol/kg body weight, with or without sustained dietary supplementation, has a neuroprotective effect and improves neurological outcomes [172–177]. Specifically, DHA administration results in a reduced lesion size and less inflammation (including TNF-α expression), reduced neuronal, oligodendrocyte and neurofilament loss, reduced macrophage/microglia recruitment and activation, and less apoptotic death, and this is correlated with an improved locomotor recovery [172–176]. DHA appears to enhance motor function recovery via its effect on the serotonin fiber input on motor neurons [177]. DHA also has a positive effect on synaptic remodeling and may enhance synaptogenesis. Immunoreactivity of synaptophysin, a synaptic vesicle protein, was found to be
less reduced after injury in DHA-treated animals compared with controls, in a rat model of cervical SCI [177].

With regard to traumatic brain injury (TBI), in the US there are 1.5-2 million new cases per year, accounting for 30% of injury-related deaths, with an annual cost of $25 billion [178]. TBI, particularly repetitive, increases susceptibility to Alzheimer’s disease, as evidenced in murine models, where repetitive TBI resulted in increased amyloid β-deposition, isoprostanes and cognitive impairment [179]. However, acute DHA administration (500 nmol/kg body weight) 30 minutes after controlled cortical impact can improve spatial memory [180]. In terms of the mechanisms involved, TBI and SCI are both associated with glutamate overflow which may be controlled via omega-3 PUFA through inhibition of voltage-sensitive Na⁺ and Ca²⁺ channels and activation of K⁺ channels [181].

DHA may also be a future treatment option for patients with stroke. In rodent ischaemic stroke models, DHA administration, acting via biosynthesis of neuroprotectin D1 (aka protectin D1), reduces astrocyte and neuronal cell death and promotes cell survival, resulting in significantly reduced total infarct volume [182,183].

Preclinical rodent models have also shown that the improved neurological outcome following acute DHA injection is not only associated with neuronal survival. Indeed, controlled cortical impact models in mice have demonstrated that ablation of astrocytes resulted in decreased neuronal survival, and increased neuroinflammation [184]. Hence, a subset of astrocytes appear to have a role in aiding neuronal survival and reducing inflammation after brain injury [185]. It has also been demonstrated that after mild compression injury in mice, heterogeneity of microglia at the site develops alongside a coordinated microglial response [186]. Following TBI, there is upregulation of a sub-population of microglia that express galectin-3/MAC-2 lectins that are involved in myelin degradation [187]. Hence the acute DHA administration appears to play a
role in modulating this complex glial response, e.g. by increasing these new and proliferating microglia and astrocytes, and ultimately resulting in decreased lesion volume.

In humans, following a single TBI, there is evidence of persistent neuroinflammation and microglial activation for up to 17 years afterwards [188,189]. This suggests that interventions using DHA may be appropriate for a longer time period following TBI rather than just in the acute phase.

In summary, preclinical models of SCI and TBI suggest that DHA, if administered in the acute phase and for some time afterwards, may help to limit progression of neurological injury and improve neurological outcomes.

7.2 Effects of omega-3 fatty acids in preclinical models of sepsis and tissue injury

Omega-3 fatty acids have been shown to have a protective effect against oedema formation in a model of septic lung failure due to the increased generation of LTB5. In perfused rabbit lung treated with *E. coli* hemolysin, EPA suppressed vascular permeability and shifted leukotriene formation from the 4-series to the 5-series compared to ARA [190]. Hence, the composition of LEs used in PN may influence microvascular changes induced by bacterial toxins.

The favorable lipid mediators formed from EPA may also have a beneficial effect on pulmonary hypertension compared to those formed from ARA. In a rabbit lung model of acute pulmonary hypertension investigating the pulmonary vasoconstrictor potencies of EPA and ARA, EPA resulted in an almost 2-fold decrease in pulmonary hypertension compared to ARA [191]. EPA is metabolized to PGI3 and TXA3 and it may be that the dominant presence of TXA3 mediates EPA’s weaker pulmonary vasoconstrictor effects, compared with ARA and ARA-derived TXA2.

In inflammatory conditions, particularly systemic inflammation with sepsis and multi-organ failure, the transmigration of monocytes through the vascular endothelium is an important
contributing factor to the pathogenesis of the condition. In an in vitro experiment investigating the effect of different free fatty acids on TNF-α activated human umbilical vein endothelial cells, EPA and DHA (but not ARA), resulted in markedly suppressed platelet-activating factor (PAF), resulting in reduced monocyte rolling and adherence, with DHA being more potent than EPA [192]. Previous work has suggested that the binding of endothelial PAF and the PAF receptor on leukocytes are responsible for the adhesive interactions of monocytes followed by their activation [193]. This mechanism involving PAF may be one factor responsible for the inflammation-dampening effect of EPA and DHA.

In a murine model of acute inflammation, pre-infusion of FO-rich LE resulted in reduced leukocyte invasion and reduced TNF-α production in the alveolar space following intra-tracheal LPS challenge, compared with SO or saline [194]. In PAF-receptor knock-out mice, the different effects of FO and SO were far less marked. This supports the hypothesis that the anti-inflammatory effect of FO is dependent on PAF/PAF-receptor linked signaling. Similarly, in a murine model of ARDS, pre-infusion with FO-containing LE resulted in greater reduction of leukocyte invasion and protein leakage into the alveolar space than either SO or SO/MCT [195]. These results suggest that the reduction in the proportion of omega-6 PUFA administered may help improve lung injury.

Extensive lymphocytic apoptosis is a hallmark feature of late-stage sepsis, and can be clearly seen in the spleen as well as other organs [196]. In a murine model of endotoxin-induced ALI, OO pre-infusion resulted in less mortality compared with SO pre-infusion [197]. Fewer lymphocytes were observed in the spleen in the SO group which appeared to be due to increased apoptosis and necrotic cell death, although both LEs resulted in increased lymphocytic apoptosis via intrinsic pathways. Hence, OO-based LEs may have fewer deleterious immunological effects than SO, at least in murine models of ALI.
In critically ill patients, a reduced flow of blood to the gut can lead to intestinal ischaemia, decreased barrier function and increased bacterial translocation. A rat endotoxin model investigating the effects of different lipid pre-infusions on microcirculation and intestinal barrier function reported improved blood flow to the intestine and less viable bacteria detected in the mesenteric lymph nodes and liver following endotoxin challenge with FO-supplemented SO/MCT compared with SO/MCT or SO alone [198]. The reduction in viable bacteria is thought to be related to improved killing of translocated bacteria rather than a reduction in translocation.

In healthy human volunteers, infusion of FO blunted the endotoxin-induced inflammatory response including suppression of monocyte generation of pro-inflammatory cytokines (TNF-α, IL-1, IL-6 and IL-8), and inhibition of monocyte-endothelium adhesion and transendothelial monocyte migration compared to SO [199]. Decreased fever in response to LPS, reduced TNF-α synthesis and a reduced LPS-induced neuroendocrine response (ACTH and noradrenaline) have also been observed with FO infusion in humans [200]. Similar protective results have been found after pre-infusion of either SO- or FO-based lipid emulsions and subsequent LPS-inhalation [201].

In summary, from preclinical models, different lipids may impact the inflammatory response of critically ill patients. SO LEs may exert negative effects in terms of increased pro-inflammatory cytokines and immune depression, such as lymphocyte destruction, whereas FO appears to dampen the inflammatory response and improve pre-clinical outcomes.

8. Conclusion

Lipids are an important component of enteral and parenteral nutrition and provide essential fatty acids, a concentrated source of calories and building blocks for cell membranes. Whilst LA-rich vegetable oil-based enteral and parenteral nutrition is still widely used, newer lipid components such as MCTs and OO appear to be safer and better tolerated than pure SO. FO-enriched
enteral and parenteral nutrition appears to be well tolerated and confers additional clinical
benefits, particularly in surgical ICU patients, due to its anti-inflammatory and immune-
modulating effects. Whilst the evidence base is not conclusive, there appears to be a potential
for FO-enriched nutrition, particularly administered peri-operatively, to reduce the rate of
complications and ICU and hospital stay in surgical ICU patients, as well as to improve
complications such as IFALD associated with SO-based LEs. The evidence for FO-based
nutrition in non-surgical ICU patients is less clear regarding its clinical benefits and additional,
well-designed large-scale clinical trials need to be conducted in this area.

Whilst FO-based PN can be more expensive than other available LEs, cost-benefit analysis has
shown that the treatment costs for ICU patients are completely offset by the savings made from
the subsequent reduction in hospital stay and reduced antibiotic costs.

Future directions regarding FO-based enteral and parenteral nutrition may include its use in TBI
and SCI, as well as in complications relating to sepsis and tissue injury, following the success of
such interventions in preclinical models.

Conflicts of Interest

P.C.C. has received speaking and advisory honoraria from Fresenius-Kabi, B. Braun,
Baxter Healthcare, Abbott Nutrition and Danone/Nutricia. M.A. has received speaking
honoraria from B. Braun, Cosmed and Danone/Nutricia. N.E.D. has received speaking
and advisory honoraria from Abbott Nutrition. T.G. has received speaking honoraria
from B. Braun and Fresenius-Kabi. S.K. has received speaking honoraria from
Fresenius-Kabi, B. Braun, Baxter Healthcare, Nutricia Poland, Nestle and Shire. S.L has
received speaking honoraria from Fresenius-Kabi, Baxter Healthcare and Abbott
Nutrition, K.M. has received speaking honoraria from Fresenius-Kabi, B. Braun, Baxter Healthcare, Abbott Nutrition, and Nestlé. A.M-T. has received grant funding from B. Braun. L.P. has received speaking honoraria and grants from Fresenius-Kabi, Amgen, CSL Behring, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Novartis, Roche, Sorin Group, and Viiv Healthcare. M.P. holds an issued patent on the treatment of parenteral nutrition-associated liver disease: a license agreement for the use of Omegaven has been signed by Boston Children’s Hospital and Fresenius Kabi. P.S. has received speaking honoraria and grants from Fresenius-Kabi, B. Braun, Baxter Healthcare and Abbott Nutrition. J.K.I. and H.V. have no conflicts to declare.
References


acids attenuate cardiopulmonary dysfunction during acute lung injury in pigs. Am J

enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in
patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study

enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with

[58] Pontes-Arruda A, Aragao AMA, Albuquerque JD. Effects of enteral feeding with
eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated

[59] Elamin EM, Miller AC, Ziad S. Immune enteral nutrition can improve outcomes in
medical-surgical patients with ARDS: a prospective randomized controlled trial. J Nutr

[60] Grau-Carmona T, Morán-García V, García-de-Lorenzo A, Heras-de-la-Calle G, Quesada-
eicosapentaenoic acid, gamma-linolenic acid and anti-oxidants on the outcome of

[61] Rice TW. Enteral omega-3 fatty acid, γ-linolenic acid, and antioxidant supplementation in


[159] Beken S, Dilli D, Fettah ND, Kabataş EU, Zenciroğlu A, Okumuş N. The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: A

Higher docosahexaenoic acid, lower arachidonic acid and reduced lipid tolerance with
high doses of a lipid emulsion containing 15% fish oil: A randomized clinical trial. Clin

[161] Deshpande G, Simmer K, Deshmukh M, Mori TA, Croft KD, Kristensen J. Fish oil
(SMOFlipid) and olive oil lipid (Clinoleic) in very preterm neonates. J Pediatr

[162] Pawlik D, Lauterbach R, Walczak M, Hurkała J, Sherman MP. Fish-oil fat emulsion
supplementation reduces the risk of retinopathy in very low birth weight infants: a

5 intravenous lipid emulsions on plasma phytosterols in preterm infants receiving
doi:10.3945/ajcn.112.056556.

lipid emulsion compared with a soybean oil-based lipid emulsion on liver chemistry and
bile acid composition in preterm infants receiving parenteral nutrition: a double-blind,


8.00029-2.


https://www.cdc.gov/traumaticbraininjury/get_the_facts.html.


Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated

versus n-6-rich lipid emulsions in murine acute lung injury-role of platelet-activating

Immunomodulation by fish-oil containing lipid emulsions in murine acute respiratory

cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med

lymphocyte apoptosis in a murine model of acute lung injury-modulation by lipid

Pscheidl E, Schywalsky M, Tschaikowsky K, Böke-Pröls T. Fish oil-supplemented
parenteral diets normalize splanchnic blood flow and improve killing of translocated

infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces
monocyte proinflammatory cytokine generation and adhesive interaction with endothelium


Figure 1. Evolution of lipid emulsions for use in parenteral nutrition.
Table 1. Macronutrient composition of EN formulas commonly used in research studies

<table>
<thead>
<tr>
<th></th>
<th>Oxepa&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Pulmocare&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Ensure Plus HN&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Impact&lt;sup&gt;3&lt;/sup&gt;</th>
<th>Reconvan&lt;sup&gt;4&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protein (g/l)</strong></td>
<td>63</td>
<td>63</td>
<td>63</td>
<td>56</td>
<td>55</td>
</tr>
<tr>
<td><strong>Carbohydrate (g/l)</strong></td>
<td>105</td>
<td>105</td>
<td>204</td>
<td>132</td>
<td>120</td>
</tr>
<tr>
<td><strong>Fat (g/l)</strong></td>
<td>93</td>
<td>93</td>
<td>(MCT, canola oil, corn oil, high oleic safflower oil)</td>
<td>49</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>33</td>
</tr>
<tr>
<td><strong>Omega-6 PUFAs (g/l)</strong></td>
<td>18.4</td>
<td>18.4</td>
<td>7.7</td>
<td>5.8</td>
<td>6.9</td>
</tr>
<tr>
<td>Of which GLA (g/l)</td>
<td>4.3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Omega-3 PUFAs (g/l)</strong></td>
<td>10</td>
<td>4.8</td>
<td>1.5</td>
<td>3.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Of which EPA + DHA (g/l)</td>
<td>6.5</td>
<td>0</td>
<td>0</td>
<td>1.7</td>
<td>2.5</td>
</tr>
<tr>
<td>Also contains</td>
<td>Taurine, carnitine, vitamin C, α-tocopherol, β-carotene</td>
<td>Taurine, carnitine, vitamin C, α-tocopherol, β-carotene</td>
<td>Vitamin C, α-tocopherol</td>
<td>Arginine, nucleotides, vitamin C, α-tocopherol, β-carotene</td>
<td>Arginine, glutamine, vitamin C, α-tocopherol, β-carotene</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: <sup>1</sup>Abbott Nutrition company website; <sup>2</sup>Taken from [68]; <sup>3</sup>Taken from [202] and Nestlé Health Science company website; <sup>4</sup>Fresenius Kabi company website.
Table 2. Fatty acids of importance in parenteral nutrition

<table>
<thead>
<tr>
<th>Fatty acid</th>
<th>Shorthand nomenclature</th>
<th>Oil source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caprylic acid</td>
<td>8:0</td>
<td>Coconut oil or palm kernel oil</td>
</tr>
<tr>
<td>Capric acid</td>
<td>10:0</td>
<td>Coconut oil or palm kernel oil</td>
</tr>
<tr>
<td>Lauric acid</td>
<td>12:0</td>
<td>Coconut oil or palm kernel oil</td>
</tr>
<tr>
<td>Myristic acid</td>
<td>14:0</td>
<td></td>
</tr>
<tr>
<td>Palmitic acid</td>
<td>16:0</td>
<td></td>
</tr>
<tr>
<td>Oleic acid</td>
<td>18:1n-9</td>
<td>Olive oil</td>
</tr>
<tr>
<td>Linoleic acid</td>
<td>18:2n-6</td>
<td>Vegetable seed oils e.g. soybean oil</td>
</tr>
<tr>
<td>α-Linolenic acid</td>
<td>18:3n-3</td>
<td>Vegetable seed oils e.g. soybean oil</td>
</tr>
<tr>
<td>Eicosapentaenoic acid</td>
<td>20:5n-3</td>
<td>Fish oil</td>
</tr>
<tr>
<td>Docosahexaenoic acid</td>
<td>22:6n-3</td>
<td>Fish oil</td>
</tr>
</tbody>
</table>
Table 3. Oil and typical fatty acid compositions (% of total) of commercially available lipid emulsions for use in parenteral nutrition

<table>
<thead>
<tr>
<th>Oil source</th>
<th>Intralipid®</th>
<th>Lipofundin® MCT/LCT</th>
<th>Structolipid®</th>
<th>Omegaven®</th>
<th>ClinOleic® (also known as Lipidem®)</th>
<th>Lipoplus®</th>
<th>SMOFlipid®</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100% soybean</td>
<td>50% MCT + 50% soybean</td>
<td>36% MCT + 64% soybean</td>
<td>100% fish*** + 20% olive soybean</td>
<td>50% MCT + 40% soybean + 10% fish*** + 30% MCT + 25% olive + 15% fish***</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SFA</td>
<td>15</td>
<td>58</td>
<td>46</td>
<td>21</td>
<td>14</td>
<td>49</td>
<td>37</td>
</tr>
<tr>
<td>MUFA*</td>
<td>24</td>
<td>11</td>
<td>14</td>
<td>23</td>
<td>64</td>
<td>14</td>
<td>33</td>
</tr>
<tr>
<td>PUFA</td>
<td>61</td>
<td>31</td>
<td>40</td>
<td>56</td>
<td>22</td>
<td>37</td>
<td>30</td>
</tr>
<tr>
<td>n-3 PUFA</td>
<td>8</td>
<td>4</td>
<td>5</td>
<td>48</td>
<td>3</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>ALA</td>
<td>8</td>
<td>4</td>
<td>5</td>
<td>1</td>
<td>3</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>EPA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>3.5</td>
<td>3</td>
</tr>
<tr>
<td>DHA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19</td>
<td>-</td>
<td>2.5</td>
<td>2</td>
</tr>
<tr>
<td>n-6 PUFA**</td>
<td>53</td>
<td>27</td>
<td>35</td>
<td>5</td>
<td>19</td>
<td>27</td>
<td>23</td>
</tr>
</tbody>
</table>

Information taken from [203], [204] and [205].

SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid

*mainly oleic acid

**mainly linoleic acid

***the fatty acid composition of fish oil is more variable than that of vegetable oils so that the precise contribution of different fatty acids may differ in different batches

Note that the fish oil used in Lipolus® is more concentrated in EPA and DHA than that used in SMOFLipid® so that 10% fish oil in Lipolus® provides more EPA and DHA than 15% fish oil in SMOFLipid®
Table 4. Clinically relevant outcomes of studies using fish oil-enriched EN in critically ill patients

<table>
<thead>
<tr>
<th>Study</th>
<th>Population (Number enrolled/included in analysis)</th>
<th>Intervention</th>
<th>EPA (g/d)</th>
<th>DHA (g/d)</th>
<th>GLA (g/d)</th>
<th>Control</th>
<th>Outcome in intervention group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Braga et al. 2002 [69]</td>
<td>Major abdominal surgery for GI malignancy (196/150)</td>
<td>Peri- &amp; post-operative IMPACT®</td>
<td>~ 2.9 EPA + DHA</td>
<td>0</td>
<td>Post-operative standard EN</td>
<td>↓ Number of complications ↓ Hospital length of stay</td>
<td></td>
</tr>
<tr>
<td>Elamin et al. 2012 [59]</td>
<td>ARDS (22/17)</td>
<td>Oxepa®</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Pulmocare®</td>
<td>↑ Oxygenation ↓ Lung injury ↓ Organ dysfunction ↓ ICU stay</td>
</tr>
<tr>
<td>Gadek et al. 1999 [56]</td>
<td>ARDS (146/98)</td>
<td>Oxepa®</td>
<td>6.9</td>
<td>2.9</td>
<td>5.8</td>
<td>Pulmocare®</td>
<td>↑ Oxygenation ↓ Ventilator days ↓ New organ failure ↓ ICU stay</td>
</tr>
<tr>
<td>Grau-Carmona et al. 2011 [60]</td>
<td>Septic patients with ALI/ARDS (160/132)</td>
<td>Oxepa®</td>
<td>5.4</td>
<td>2.3</td>
<td>4.9</td>
<td>Ensure Plus HN®</td>
<td>↑ Oxygenation ↓ New organ failure ↓ ICU stay</td>
</tr>
<tr>
<td>Kagan et al. 2015 [71]</td>
<td>Severe trauma (120/99)</td>
<td>Oxepa®</td>
<td>5.5</td>
<td>2.3</td>
<td>4.7</td>
<td>Pulmocare®</td>
<td>No effect on oxygenation, incidence of ARDS/ALI, length of ventilation time, length of ICU stay or 28-day mortality</td>
</tr>
<tr>
<td>Klek et al. 2011 [70]</td>
<td>Major abdominal surgery for GI malignancy (341/305)</td>
<td>Post-operative Reconvan®</td>
<td>~ 5 EPA + DHA</td>
<td>0</td>
<td>Post-operative Peptisorb®</td>
<td>↓ Hospital stay ↓ Infectious complications ↓ Overall morbidity ↓ Overall mortality</td>
<td></td>
</tr>
<tr>
<td>Pontes-Arruda et al. 2006 [58]</td>
<td>ARDS secondary to sepsis/septic shock (165/103)</td>
<td>Oxepa®</td>
<td>4.9</td>
<td>2.2</td>
<td>4.6</td>
<td>Pulmocare®</td>
<td>↑ Oxygenation ↓ New organ failure ↓ Ventilator days ↓ ICU stay ↓ Mortality</td>
</tr>
<tr>
<td>Study Authors and Year</td>
<td>Condition</td>
<td>Intervention</td>
<td>EPA + DHA</td>
<td>Nutrient</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>-----------</td>
<td>----------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pontes-Arruda et al. 2011 [68]</td>
<td>Early stage sepsis (115/106)</td>
<td>Oxepa®</td>
<td>4.6</td>
<td>2.0</td>
<td>Ensure Plus HN® ↓ Progression of sepsis ↓ Respiratory and cardiac failure ↓ ICU stay</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rice et al. 2011 [61]</td>
<td>ARDS/ALI (272/272)</td>
<td>Bolus FO + GLA</td>
<td>6.8</td>
<td>3.4</td>
<td>Equivalent with no FO or GLA No clinical benefit. Trial stopped early due to fewer ventilator-free and ICU-free days, and greater 60-day mortality in FO group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singer et al. 2006 [57]</td>
<td>ALI (100/95)</td>
<td>Oxepa®</td>
<td>5.4</td>
<td>2.5</td>
<td>Pulmocare® ↑ Oxygenation ↓ Ventilator duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stapleton et al. 2011 [62]</td>
<td>ALI (90/85)</td>
<td>Bolus FO</td>
<td>9.8</td>
<td>6.8</td>
<td>Equivalent with no FO No effect on SOFA, ventilator free days or mortality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Zanten et al. 2014 [73]</td>
<td>Medical/surgical/trauma ICU patients</td>
<td>Experimental high protein feed enriched with glutamine, omega-3 fatty acids &amp; antioxidants</td>
<td>~ 4.5</td>
<td>0</td>
<td>Protison (high protein feed) No effect on infections, mortality, organ failure, duration of mechanical ventilation or length of stay. Increased 6-month mortality rate reported in medical sub-group.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SOFA, Sequential Organ Failure Assessment score.
<table>
<thead>
<tr>
<th>Study Description</th>
<th>Population</th>
<th>Intervention</th>
<th>Duration</th>
<th>Control</th>
<th>Outcome in intervention group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badía-Tahull et al. 2010 [95]</td>
<td>Gastrointestinal surgery</td>
<td>OO/SO + FO (ClinOleic® + Omegaven®) (n=13)</td>
<td>5 d</td>
<td>OO/SO (ClinOleic®) (n=14)</td>
<td>↓ Number of infections. Trend towards lower mortality and fewer incidences of sepsis. No effect on length of hospital stay</td>
</tr>
<tr>
<td>Berger et al. 2008 [206]</td>
<td>Abdominal aorta aneurysm surgery</td>
<td>SO/MCT/FO (Lipoplus®) (n=12)</td>
<td>4 d</td>
<td>SO/MCT (Lipofundin®) (n=12)</td>
<td>Trend towards shorter ICU and hospital stay</td>
</tr>
<tr>
<td>Berger et al. 2013 [89]</td>
<td>Cardiac surgery</td>
<td>FO (Omegaven®) (n=14)</td>
<td>3 infusions: 12 h and 2 h before surgery and immediately after surgery</td>
<td>Saline (n=14)</td>
<td>Trend towards shorter length of mechanical ventilation and shorter ICU stay</td>
</tr>
<tr>
<td>Grimm et al. 2006 [97]</td>
<td>Gastrointestinal surgery</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=19)</td>
<td>5 d</td>
<td>SO (Lipovenoes®) (n=14)</td>
<td>↓ Length of hospital stay</td>
</tr>
<tr>
<td>Han et al. 2012 [105]</td>
<td>Major surgery</td>
<td>SO/MCT + FO (Lipofundin® + Omegaven®) (n=18)</td>
<td>7 d post-surgery</td>
<td>SO/MCT (Lipofundin®) (n=12)</td>
<td>Trend towards less liver dysfunction and fewer infections</td>
</tr>
<tr>
<td>Heidt et al. 2009 [99]</td>
<td>Coronary artery bypass surgery</td>
<td>FO (Omegaven®) (n=52)</td>
<td>~12 h prior to surgery until ward transfer</td>
<td>SO (Lipovenoes®) (n=50)</td>
<td>↓ Post-operative atrial fibrillation ↓ ICU stay</td>
</tr>
<tr>
<td>Heller et al. 2004 [106]</td>
<td>Gastrointestinal surgery</td>
<td>SO + FO (Lipovenoes® + Omegaven®) (n=24)</td>
<td>5 d post-surgery</td>
<td>SO (Lipovenoes®) (n=20)</td>
<td>↓ Markers of liver dysfunction</td>
</tr>
<tr>
<td>Jiang et al. 2010 [91]</td>
<td>Gastrointestinal surgery</td>
<td>SO + FO (Intralipid® + Omegaven®) (n=100)</td>
<td>7 d post-surgery</td>
<td>SO (Intralipid®) (n=103)</td>
<td>↓ SIRS ↓ Length of hospital stay Trend towards fewer</td>
</tr>
<tr>
<td>Study</td>
<td>Type</td>
<td>Intervention</td>
<td>Duration</td>
<td>Comparator</td>
<td>Outcomes</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------</td>
<td>-----------</td>
<td>-------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>Klek et al. 2005 [94]</td>
<td>Gastrointestinal surgery</td>
<td>Post-operative FO (Omegaven®) (n=30)</td>
<td>Mean duration 9 d</td>
<td>SO/MCT (Lipofundin®) (n=30) SO/MCT + glutamine (Lipofundin®+ Dipeptiven®) (n=30)</td>
<td>↓ Infectious complications ↓ Hospital stay</td>
</tr>
<tr>
<td>Ma et al. 2012 [108]</td>
<td>Gastrointestinal surgery</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=20)</td>
<td>5 d post-surgery</td>
<td>SO/MCT (Lipovenoes®) (n=20)</td>
<td>No difference in post-operative complications, infections or duration of hospital stay</td>
</tr>
<tr>
<td>Mateu-de Antonio et al. 2008 [85]</td>
<td>Surgery patients</td>
<td>OO/SO (ClinOleic®) (n=23)</td>
<td>Mean duration 19 d</td>
<td>SO (Intralipid®) (n=16)</td>
<td>No difference in number and type of infections, ICU stay, hospital stay or mortality</td>
</tr>
<tr>
<td>Metry et al. 2014 [109]</td>
<td>Gastrointestinal surgery</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=41)</td>
<td>7 d post-surgery</td>
<td>SO (Intralipid®) (n=42)</td>
<td>No difference in ventilation, duration of ICU or hospital stay or mortality</td>
</tr>
<tr>
<td>de Miranda Torrinhas et al. 2013 [92]</td>
<td>Gastrointestinal surgery</td>
<td>Pre-operative FO (Omegaven®) (n=31)</td>
<td>3 d pre-surgery</td>
<td>SO/MCT (Lipovenoes®) (n=32)</td>
<td>No effect on post-operative infections, length of ICU or hospital stay.</td>
</tr>
<tr>
<td>Tsekos et al. 2004 [100]</td>
<td>Gastrointestinal surgery</td>
<td>Perioperative SO/MCT + FO (Omegaven®) (n=53) vs Post-operative SO/MCT + FO (Omegaven®) (n=86)</td>
<td>2-3 d pre-surgery followed by 5 d post-surgery</td>
<td>SO/MCT (brand undisclosed) (n=110)</td>
<td>Perioperative: ↓ Mortality ↓ Number of patients requiring ventilation ↓ Hospital stay No change in length of ICU stay</td>
</tr>
<tr>
<td>Umpierrez et al. 2012 [84]</td>
<td>Surgery</td>
<td>OO/SO (ClinOleic®) (n=51)</td>
<td>28 d post-surgery</td>
<td>SO (Intralipid®) (n=49)</td>
<td>No difference in mortality, infections or length of stay</td>
</tr>
<tr>
<td>Study</td>
<td>Type of Surgery</td>
<td>Fat Emulsion &amp; Administration</td>
<td>Time post-surgery</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------------------------------</td>
<td>-------------------------------</td>
<td>------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Wang et al. 2012 [104]</td>
<td>Gastrointestinal surgery</td>
<td>SO/MCT/FO (Lipoplus®) (n=32)</td>
<td>5 d post-surgery</td>
<td>SO/MCT (Lipofundin®) (n=31) ↓ Total bilirubin</td>
<td></td>
</tr>
<tr>
<td>Weiss et al. 2002 [90]</td>
<td>Surgery (n=24)</td>
<td>Peri-operative FO (Omegaven®)</td>
<td>d-1 to d 5</td>
<td>SO (Lipovenoes®) ↓ Length of hospital stay. No effect on infection rate or mortality.</td>
<td></td>
</tr>
<tr>
<td>Wu et al. 2014 [110]</td>
<td>Gastrointestinal surgery</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=20)</td>
<td>5 d post</td>
<td>MCT/SO (Lipovenoes®) (n=15) No difference in infections, duration of hospital stay or mortality</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Population</td>
<td>Intervention</td>
<td>Duration</td>
<td>Control</td>
<td>Outcome</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------</td>
<td>----------</td>
<td>----------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Barbosa et al. 2010 [119]   | Critically ill with sepsis/SIRS | SO/MCT/FO (Lipoplus®) (n=13)                      | 5 d      | SO/MCT (part of LipidSpecial®) (n=10)       | ↑ PO$_2$/FiO$_2$ ratio  
↓ Length of hospital stay for surviving patient sub-group. No difference in ventilation days, length of ICU stay or mortality |
| Barros et al. 2013, 2014 [208,209] | Elderly ICU patients on EN | Supplementary FO (Omegaven®) (n=15)              | 6 h infusions / d for 3 d | No supplementary PN (n=25)                    | ↑ Gas exchange  
Trend towards shorter length of mechanical ventilation and decreased mortality. No effect on liver function |
| Burkhart et al. 2014 [120]  | Sepsis                      | FO (Omegaven®) (n=25)                            | 7 d      | Standard care (n=25)                        | No difference in duration of ICU stay or mortality                                                                                                                                             |
| Edmunds et al. 2014 [115]   | Mechanically ventilated critically ill | FO-enriched lipids (SMOFlipid®, Lipoplus® or Omegaven®) (n=19) OO/SO (ClinOleic®) (n=74) | ≥ 5 d    | SO-based lipids (various brands) (n=223) Lipid-free (n=70) SO/MCT (various brands) (n = 65) | For FO-enriched lipids:  
↓ Duration of mechanical ventilation  
↓ Length of ICU stay  
↓ Mortality |
| Friesercke et al. 2008 [126] | Medical ICU                 | SO/MCT + FO (Lipofundin® + Omegaven®) (n=63)    | ≥ 6 d    | SO/MCT (Lipofundin®) (n=60)                 | No effect on infection, duration of mechanical ventilation, length of ICU stay or 28-day mortality                                                                                                 |
| García-de-Lorenzo et al. 2005 [210] | Severe burns                | OO/SO (ClinOleic®) (n=11)                        | 6 d      | SO/MCT (Lipofundin®) (n=11)                 | No effect on organ dysfunction, requirement for ventilation, number of infections, length of ICU or hospital stay or mortality                                                                   |
| Grau-Carmona et al. 2015 [123] | Medical and surgical ICU    | SO/MCT/FO (Lipoplus®) (n=58)                     | ≥ 5 d    | SO/MCT (Lipofundin®) (n=59)                 | ↓ Nosocomial infections  
No difference in duration of ventilation, length of ICU or hospital stay or 6-month |
<table>
<thead>
<tr>
<th>Study</th>
<th>Condition</th>
<th>Intervention</th>
<th>Duration</th>
<th>Control Intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gupta et al. 2011 [211]</td>
<td>ARDS on EN</td>
<td>Supplemental FO (Omegaven®) (n=31)</td>
<td>14 d</td>
<td>Standard EN (n=30)</td>
<td>No difference in duration of ventilation, ICU stay or hospital stay</td>
</tr>
<tr>
<td>Hall et al. 2014 [118]</td>
<td>Critically ill with sepsis</td>
<td>FO (Omegaven®) (n=30)</td>
<td>14 d or to discharge</td>
<td>Standard care (N=30)</td>
<td>↓ SOFA \  ↓ Mortality in less severe sepsis subgroup \  No effect on length of stay</td>
</tr>
<tr>
<td>Khor et al. 2011 [121]</td>
<td>Severe sepsis</td>
<td>FO (Omegaven®) (n=14)</td>
<td>5 d</td>
<td>Saline (n=13)</td>
<td>No effect on length of stay</td>
</tr>
<tr>
<td>Mayer et al. 2003 [122]</td>
<td>Septic shock</td>
<td>FO (Omegaven®) (n=10)</td>
<td>5 d</td>
<td>SO (Lipoven®) (n=11)</td>
<td>No effect on mortality or length of mechanical ventilation</td>
</tr>
<tr>
<td>Mayer et al. 2003 [117]</td>
<td>Septic shock</td>
<td>FO (Omegaven®) (n=5)</td>
<td>10 d</td>
<td>SO (Lipoven®) (n=5)</td>
<td>Trend towards shorter ventilation time. \  No mortality in either group</td>
</tr>
<tr>
<td>Sabater et al. 2008 [212]</td>
<td>ARDS</td>
<td>SO/MCT/FO (Lipoplus®) (n=8)</td>
<td>12 h</td>
<td>SO (Intralipid®) (n=8)</td>
<td>No effect on gas exchange or mortality</td>
</tr>
<tr>
<td>Wang et al. 2008 [116]</td>
<td>Acute pancreatitis</td>
<td>SO + FO (Lipovenoes® + Omegaven®) (n=20)</td>
<td>5 d</td>
<td>SO (Lipovenoes®) (n=20)</td>
<td>↓ Requirement for renal replacement therapy \  ↑ Oxygenation index \  Trend towards fewer infections and shorter length of ICU and hospital stay</td>
</tr>
<tr>
<td>Zhu et al. 2012 [98]</td>
<td>Liver transplantation</td>
<td>FO (Omegaven®) (n=33)</td>
<td>7 d post-surgery</td>
<td>SO/MCT (20% emulsion with a 1:1 ratio) (n=33)</td>
<td>↓ Length of hospital stay</td>
</tr>
</tbody>
</table>

SOFA, Sequential Organ Failure Assessment.
<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Duration</th>
<th>Control</th>
<th>Outcome in intervention group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beken et al. 2014 [159]</td>
<td>Very low birth weight preterm infants</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=40)</td>
<td>Mean: 14 d</td>
<td>SO (Intralipid®) (n=40)</td>
<td>↓ Retinopathy of prematurity No difference in morbidity or mortality outcomes</td>
</tr>
<tr>
<td>D'Ascenzo et al. 2014 [160]</td>
<td>Very low birth weight preterm infants</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=30)</td>
<td>7 d following birth</td>
<td>SO (Intralipid®) (n=32)</td>
<td>↑ Plasma EPA and DHA ↓ Plasma ARA ↑ Serum triglycerides, plasma phospholipids, free cholesterol No difference in weight.</td>
</tr>
<tr>
<td>Deshpande et al. 2014 [161]</td>
<td>Preterm neonates</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=17)</td>
<td>7 d</td>
<td>OO/SO (ClinOleic®) (n=17)</td>
<td>↑ RBC EPA ↑ Vitamin E ↓ F₂ isoprostanes</td>
</tr>
<tr>
<td>Larsen et al. 2012 [166]</td>
<td>Infants undergoing open heart surgery</td>
<td>SO/MCT/FO (Lipoplus®) (n=16)</td>
<td>1-4 d before and 10 d post-surgery</td>
<td>SO (Intralipid®) (n=16)</td>
<td>↓ TNF-α No difference in clinical outcomes</td>
</tr>
<tr>
<td>Larsen et al. 2015 [165]</td>
<td>Infants undergoing open heart surgery</td>
<td>SO/MCT/FO (Lipoplus®) (n=16)</td>
<td>3 d pre-op and 5 d post-op</td>
<td>SO (Intralipid®) (n=16)</td>
<td>↑ Plasma phospholipid EPA ↓ Plasma LTB₄ and lymphocytes</td>
</tr>
<tr>
<td>Pawlik et al. 2013 [162]</td>
<td>Very low birthweight preterm infants</td>
<td>OO/SO+FO (ClinOleic® + Omegaven®) (n=60)</td>
<td>28 d</td>
<td>OO/SO (ClinOleic®) (n=70)</td>
<td>↑ Plasma DHA ↓ Cholestasis</td>
</tr>
<tr>
<td>Savini et al. 2013 [163]</td>
<td>Very low birthweight preterm infants</td>
<td>SO (Intralipid®) (n=30) vs SO/MCT (Lipofundin®)(n=30) vs SO/MCT/FO</td>
<td>21 d</td>
<td>--</td>
<td>Lowest plasma phytosterols in SMOFlipid® group No difference in liver function</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>Formula</td>
<td>Duration</td>
<td>Results</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>---------</td>
<td>----------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Vlaardingerbroek et al. 2014 [158], Roelands et al. 2016 [134]</td>
<td>Very low birth weight infants</td>
<td>SO/MCT/OO/FO (SMOFlipid®) (n=48)</td>
<td>Median: 11 d</td>
<td>↑ Plasma EPA and DHA ↑ Weight gain No difference in ARA. No differences in morbidity, mortality or other biochemical outcomes No difference in neurodevelopmental outcome</td>
<td></td>
</tr>
<tr>
<td>Wang et al. 2016 [164]</td>
<td>Preterm infants</td>
<td>OO/SO (ClinOleic®) (n=50)</td>
<td>14 d</td>
<td>↓ Direct bilirubin Differences in bile acid composition No difference in clinical outcome</td>
<td></td>
</tr>
</tbody>
</table>